HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 02-04-2010, 07:00 AM   #1
Joe
Webmaster
 
Joe's Avatar
 
Join Date: Feb 2005
Location: Home of the "Flying Tomato" Carlsbad, CA
Posts: 2,036
Images: 5
San Antonio Summary

After a long search, our organization has finally located an oncologist to interpret news releases. Here is what they felt were the highlights of December's San Antonio Meeting.

Regards
Joe



Highlights from San Antonio Breast Conference 2009

(1) Trastuzumab in Combination with Lapatinib is better than Lapatinib alone for metastatic disease
Kimberly Blackwell, MD, from Duke University, presented data that women with metastatic breast cancer who received trastuzumab in combination with lapatinib had an improvement in overall survival compared to those who received lapatinib alone. This study (EGF104900) randomized 296 patients with metastatic HER2-positive breast cancer to either lapatinib or lapatinib in combination with weekly trastuzumab. Approximately 30% of patients had received 6 or more prior chemotherapy regimens, and had received a median of 3 prior trastuzumab regimens for metastatic disease. The overall response rate was 6.9% in the lapatinib alone arm compared to 10.3% in the combination arm, with a 2.9 month improvement in median overall survival (9.5 vs 14.0 months). This survival advantage was seen even in the setting of 52% of patients in the single agent lapatinib arm undergoing a planned cross over to the combination arm at the time of progression. There was also no increase in cardiac toxicity in the combination. This results in particularly impressive since the majority of patients had progressed on several trastuzumab-based regimens.

(2) Trastuzumab-DM1 (T-DM1) in patients with HER2-metastatic breast cancer
Ian Krop, MD, PhD, from Dana-Farber Cancer Institute, presented a phase II study of T-DM1 for women with metastatic HER2-positive breast cancer. T-DM1 is a novel anti-HER2 antibody drug conjugate in development for the treatment of metastatic HER2-positive breast cancer. This agent combines the targeting properties of trastuzumab to the HER2-receptor along with the delivery of a chemotherapy agent, DM1. This study was a multi-institutional single-arm phase II study of 100 patients who had received prior anthracycline, taxane, capecitabine, lapatinib, and trastuzumab, with at least two prior HER2-directed regimens in the metastatic setting. Patients received T-DM1 at 3.6 mg/kg IV every 3 weeks. There was a 32.7% objective response rate found. This is particularly impressive in a population with a median time from metastatic diagnosis of over 3 years and over 2 years of prior HER2-directed therapy. T-DM1 was well-tolerated with no evidence of dose-limiting cardiotoxicity. It is anticipated that Genentech/Roche will seek accelerated approval for T-DM1, however it is unclear if approval will be made prior to the results of ongoing phase III studies. One phase III study with T-DM1 that is open is the EMILIA study. This study is compares T-DM1 to capecitabine+lapatinib for second-line therapy of HER2-positive metastatic breast cancer.

(3) Updated results from BCIRG 006: Slight advantage for adjuvant anthracycline-based regimen compared to the taxane-based treatment
Dennis Slamon, MD, PhD, from the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, presented the third analysis of the BCIRG 006 study. This trial compares chemotherapy alone (adriamycin+ cytoxan, followed by taxotere, ACT) to chemotherapy with herceptin (ACTH), and to a non-anthracycline-based chemotherapy regimen (taxotere+carboplatin+herceptin, TCH). In more than 3000 women, at 5 years, there were 29 fewer events in the anythracycline-based group than in the taxane-based group. This resulted in a 3% difference in disease-free survival between the two groups. Dr. Slamon felt that the differences in efficacy were outweighed by the toxicities. There was an increased risk of congestive heart failure (CHF) in the anthracycline-based chemotherapy group compared to the taxane-based treatment group (21 vs 4 cases of CHF). There were also 8 total cases of treatment-related leukemias, 6 among patients in the ACT group, 1 in the ACTH group, and 1 in the TCH group. However, others would argue that many of the cases of CHF among the patients in the anthracycline-group were reversible, and that there was not a difference in the number of cases of leukemia between the ACTH and TCH arms. Overall, there appears to be a slight advantage in efficacy for anthracyline-based adjuvant therapy compared to the taxane-based treatment, however longer-term follow-up is still needed.

(4) Updated results from N9831: Sequential trastuzumab also lower risk of recurrence
Edith Perez, MD, chair of the North Central Cancer Treatment Group Breast Committee, presented updated results of the N9831 study. After a median follow-up of 5.5 years, disease-free survival (DFS) was 84.1% for concurrent chemotherapy and trasuzumab, 80.1% for chemotherapy with sequential trastuzumab and 71.9% for chemotherapy alone. While there was not a statistically significant difference in DFS between the concurrent vs sequential treatment, there is a trend towards superiority of the concurrent treatment arm. Prior results had suggested that there was no benefit for sequential chemotherapy followed by trastuzumab compared to chemotherapy alone, however, these updated results suggest a statistically significant benefit of the sequential treatment compared to chemotherapy alone (p=0.005) In terms of cardiac safety, there was a 3.3% incidence of CHF for concurrent therapy compared to 2.8% for sequential therapy. While the benefit of trastuzumab appears greatest when given concurrently with chemotherapy, there is still some benefit to sequential trastuzumab compared to chemotherapy alone.

(5) Heavy consumption of alcohol may increase breast cancer recurrence
Dr. Marilyn Kwan, PhD, from Kaiser Permanente in Oakland, California, examined the association between alcohol intake and cancer recurrence and mortality in the Life After Cancer Epidemiology (LACE) Study, a prospective cohort study of 1897 early-stage breast cancer patients. After 8 years of follow-up, there were 349 breast cancer recurrence (18%) and 332 deaths (17%), with 57% of deaths attributable to breast cancer. Among those who drank 3-4 drinks per week, or more, there was a 1.3-fold increased risk of breast cancer recurrence, and a 1.5-fold increased risk of death due to breast cancer. This increased risk of recurrence was more pronounced in postmenopausal patients and obese patients. Based on these findings, some have recommending limiting alcohol intake to less than 3 drinks per week, particularly for those who are postmenopausal and obese.
__________________
A Proud webmaster to the internet's most informed, educated, COMPASSIONATE and caring group of breast cancer survivors.

Illegitimi non carborundum


My Album
Joe is offline   Reply With Quote
Old 02-04-2010, 11:36 AM   #2
ElaineM
Senior Member
 
ElaineM's Avatar
 
Join Date: May 2006
Posts: 3,142
Wink Re: San Antonio Summary

Thank you very much Joe !!
__________________
Peace,
ElaineM
12 years and counting
http://her2support.org/vbulletin/showthread.php?t=48247
Lucky 13 !! I hope so !!!!!!
http://her2support.org/vbulletin/showthread.php?t=52807
14 Year Survivor
http://her2support.org/vbulletin/showthread.php?t=57053
"You never know how strong you are until being strong is the only choice you have." author unknown
Shared by a multiple myeloma survivor.
ElaineM is offline   Reply With Quote
Old 02-04-2010, 03:22 PM   #3
karen z
Senior Member
 
Join Date: Apr 2008
Posts: 1,477
Re: San Antonio Summary

What a great service this will be for everyone.
Thank you!
Karen
karen z is offline   Reply With Quote
Old 02-04-2010, 07:01 PM   #4
Jackie07
Senior Member
 
Jackie07's Avatar
 
Join Date: Jan 2008
Location: "Love never fails."
Posts: 5,808
Re: San Antonio Summary

Thank you, thank you, thank you.
__________________
Jackie07
http://www.kevinmd.com/blog/2011/06/doctors-letter-patient-newly-diagnosed-cancer.html
http://www.asco.org/ASCOv2/MultiMedi...=114&trackID=2

NICU 4.4 LB
Erythema Nodosum 85
Life-long Central Neurocytoma 4x5x6.5 cm 23 hrs 62090 semi-coma 10 d PT OT ST 30 d
3 Infertility tmts 99 > 3 u. fibroids > Pills
CN 3 GKRS 52301
IDC 1.2 cm Her2 +++ ER 5% R. Lmptmy SLNB+1 71703 6 FEC 33 R Tamoxifen
Recc IIB 2.5 cm Bi-L Mast 61407 2/9 nds PET
6 TCH Cellulitis - Lymphedema - compression sleeve & glove
H w x 4 MUGA 51 D, J 49 M
Diastasis recti
Tamoxifen B. scan
Irrtbl bowel 1'09
Colonoscopy 313
BRCA1 V1247I
hptc hemangioma
Vertigo
GI - > yogurt
hysterectomy/oophorectomy 011410
Exemestane 25 mg tab 102912 ~ 101016 stopped due to r. hip/l.thigh pain after long walk
DEXA 1/13
1-2016 lesions in liver largest 9mm & 1.3 cm onco. says not cancer.
3-11 Appendectomy - visually O.K., a lot of puss. Final path result - not cancer.
Start Vitamin D3 and Calcium supplement (600mg x2)
10-10 Stopped Exemestane due to r. hip/l.thigh pain OKed by Onco 11-08-2016
7-23-2018 9 mm groundglass nodule within the right lower lobe with indolent behavior. Due to possible adenocarcinoma, Recommend annual surveilence.
7-10-2019 CT to check lung nodule.
1-10-2020 8mm stable nodule on R Lung, two 6mm new ones on L Lung, a possible lymph node involvement in inter fissule.
"I WANT TO BE AN OUTRAGEOUS OLD WOMAN WHO NEVER GETS CALLED AN OLD LADY. I WANT TO GET SHARP EDGED & EARTH COLORED, TILL I FADE AWAY FROM PURE JOY." Irene from Tampa

Advocacy is a passion .. not a pastime - Joe
Jackie07 is offline   Reply With Quote
Old 02-04-2010, 07:12 PM   #5
caya
Senior Member
 
caya's Avatar
 
Join Date: Jan 2007
Location: Thornhill, Ontario Canada
Posts: 2,320
Re: San Antonio Summary

Thanks Joe, this is so helpful...

all the best
caya
__________________
ER90%+/PR 50%+/HER 2+
1.7 cm and 1.0 cm.
Stage 1, grade 2, Node Negative (16 nodes tested)
MRM Dec.18/06
3 x FEC, 3 x Taxotere
Herceptin - every 3 weeks for a year, finished May 8/08

Tamoxifen - 2 1/2 years
Femara - Jan. 1, 2010 - July 18, 2012
BRCA1/BRCA2 Negative
Dignosed 10/16/06, age 48 , premenopausal
Mild lymphedema diagnosed June 2009 - breast surgeon and lymph. therapist think it's completely reversible - hope so.
Reclast infusion January 2012
Oopherectomy October 2013
15 Years NED!!
caya is offline   Reply With Quote
Old 02-04-2010, 10:44 PM   #6
Chelee
Senior Member
 
Chelee's Avatar
 
Join Date: Feb 2006
Location: Southern, CA
Posts: 2,511
Re: San Antonio Summary

Excellent Joe...thanks SO much!

Chelee
__________________
DX: 12-20-05 - Stage IIIA, Her2/Neu, 3+++,Er & Pr weakly positive, 5 of 16 pos nodes.
Rt. MRM on 1-3-06 -- No Rads due to compromised lungs.
Chemo started 2-7-06 -- TCH - - Finished 6-12-06
Finished yr of wkly herceptin 3-19-07
3-15-07 Lt side prophylactic simple mastectomy. -- Ooph 4-05-07
9-21-09 PET/CT "Recurrence" to Rt. axllia, Rt. femur, ilium. Possible Sacrum & liver? Now stage IV.
9-28-09 Loading dose of Herceptin & started Zometa
9-29-09 Power Port Placement
10-24-09 Mass 6.4 x 4.7 cm on Rt. femur head.
11-19-09 RT. Femur surgery - Rod placed
12-7-09 Navelbine added to Herceptin/Zometa.
3-23-10 Ten days of rads to RT femur. Completed.
4-05-10 Quit Navelbine--Herceptin/Zometa alone.
5-4-10 Appt. with Dr. Slamon to see what is next? Waiting on FISH results from femur biopsy.
Results to FISH was unsuccessful--this happens less then 2% of the time.
7-7-10 Recurrence to RT axilla again. Back to UCLA for options.
Chelee is offline   Reply With Quote
Old 02-05-2010, 12:33 AM   #7
sarah
Senior Member
 
Join Date: Sep 2005
Location: france
Posts: 1,648
Re: San Antonio Summary

this is fantastic to have a translation! many thanks Joe. Do they ever mention how deadly dairy products are to BC patients? which is why there is less in countries where it isn't part of the diet such as Asia where BC is called the "rich woman's" disease because of that?
All the anti-cancer books I've read mention dairy as deadly.
Living here in the country of fromage, it's tough to avoid!
sarah
__________________
sarah is offline   Reply With Quote
Old 02-05-2010, 10:49 PM   #8
Catherine
Senior Member
 
Catherine's Avatar
 
Join Date: Dec 2006
Location: Oregon
Posts: 715
Re: San Antonio Summary

Joe, Thank you so very much for finding someone to translate for us non-propeller heads. I appreciated being able to read the newest information from ASCO.

Thank you to you and Christine.

Catherine
__________________
Catherine


Found my own lump in the shower
April 2006 at the age of 58
Stage IIB, ER- PR- HER2+++ multi focal tumors, largest 2.3cm
Chemo first: AC/Taxol over 16 weeks
Bilateral mastectomy Sep 06
33 rads after the surgery
1 year of Herceptin completed Dec 07
15 years and no recurrence as of April 2021
Catherine is offline   Reply With Quote
Old 02-06-2010, 02:48 PM   #9
Lien
Senior Member
 
Lien's Avatar
 
Join Date: May 2006
Location: Haarlem, the Netherlands
Posts: 835
Re: San Antonio Summary

Sarah: I live in the Netherlands, cheese country. I wonder whether it's the dairy or the hormones in milk that cause this increase. Anyway, I am allergic to milk and cheese, haven't had any since I was 16 and developed BC anyway. So it may contribute, but it's certainly not the only cause.

And Joe: THANKS!!!!! For this and for everything you are doing for us. You're a CHAMP!

Jacqueline
__________________
Diagnosed age 44, January 2004, 0.7 cm IDC & DCIS. Stage 1, grade 3, ER/PR pos. HER2 pos. clear margins, no nodes. SNB. 35 rads. On Zoladex and Armidex since Dec. 2004. Stopped Zoladex/Arimidex sept 2009 Still taking mistletoe shots (CAM therapy) Doing fine.
Lien is offline   Reply With Quote
Old 02-07-2010, 10:57 AM   #10
Christine MH-UK
Senior Member
 
Join Date: Sep 2005
Posts: 414
Re: San Antonio Summary

Great, Joe. Really appreciated the Perez update.
Christine MH-UK is offline   Reply With Quote
Old 02-07-2010, 02:12 PM   #11
krisvell
Senior Member
 
krisvell's Avatar
 
Join Date: Sep 2009
Location: Kensington, CT
Posts: 394
Re: San Antonio Summary

Thank you Joe. I can actually understand it.
Kris...
__________________
06/08/09 - 55, IDC, IIIA, ER+/PR-/HER+++
Nottingham 6/9 - Grade 2 5.2cm, several nodes
06/23/09 - Neoadjuvant - TCH Herceptin til June
10/07/09 - Finished Chemo
10/27/09 - Mastectomy RB
Path Report: RB No residual tumor pCR,
2 of 15 pos - .5mm largest micromets
12/18/09 - Radiation started (28)
02/05/10 - Finished Radiation
01/11/10 - Started Femara
06/22/10 - Finished Herceptin.. My son's 22nd BD. Hope it's a sign! Hoping for the best.
11/15/10 - Started Walter Reed BC Vaccine trial at
1/04/11 - Sibley Mem. Had to withdraw due to met
01/23/11 - Stage IV - Brain Met 1.6cm 1.7cm
02/03/11 - Gamma Knife (2 fracts to minmize necrosis)
03/01/11 - Gamma Knife
6/11 - Necrosis
7/11 - Necrosis stopped & Tumor progression
8/11 = Now think it's really necrosis
9/11 - Avastin every two weeks -- It's working!! Necrosis is shrinking.
12/11 - Necrosis gone AVASTIN worked.
12/11 - Bone &CT found


Oct '10 - Ran Hartford 1/2 Marathon to Thank Dr. Slamon for Herceptin!
krisvell is offline   Reply With Quote
Old 02-07-2010, 02:48 PM   #12
Rich66
Senior Member
 
Rich66's Avatar
 
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
Re: San Antonio Summary

The leukemia numbers in BCIRG 006 are a bit of a downer. are these "statistically significant"?
__________________

Mom's treatment history (link)
Rich66 is offline   Reply With Quote
Old 02-07-2010, 08:47 PM   #13
suzan w
Senior Member
 
suzan w's Avatar
 
Join Date: Sep 2005
Location: Naples FL
Posts: 1,744
Re: San Antonio Summary

thank you Joe!!
__________________
Suzan W.
age 54 at diagnosis
5/05 suspicious mammogram-left breast
5/05 biopsy-invasive lobular carcinoma with LCIS,8mm tumor,stage 1 grade 2, ER+ PR+ Her2+++
6/14/05 bilateral mastectomy, node neg. all scans neg.
Oncotype DX-high risk
8/05-10/05 4 rounds A/C
10/05 -10/06 1 yr. herceptin
arimidex-5 years
2/14/08 started daily self administered injections..FORTEO for severe osteoporosis
7/28/09 BRCA 1 negative BRCA2 POSITIVE
8/17/09 prophylactic salpingo-oophorectomy
10/15/10 last FORTEOinjection
RECLAST infusion(ostoeporosis)
6/14/10 5 year cancerversary!
8/2010-18%increase in bone density!
no further treatments
Oncologist says, "Go do the Happy Dance"
I say,"What a long strange trip its been"
'One day at a time'
6-14-2015. 10 YEAR CANCERVERSARY!
7-16 to 9-16. Extensive (and expensive) dental work done to save teeth. Damage from osteoporosis and chemo and long term bisphosphonate use
6-14-16. 11 YEAR CANCERVERSARY!!
7-20-16 Prolia injection for severe osteoporosis
2 days later, massive hive outbreak. This led to an eventual dx of Chronic Ideopathic Urticaria, an auto-immune disease from HELL.
6-14-17 12 YEAR CANCERVERSARY!!
still suffering from CIU. 4 hospitilizations in the past year

as of today, 10-31-17 in remission from CIU and still, CANCER FREE!!!
6-14-18 13 YEAR CANCERVERSARY!! NED!!
suzan w is offline   Reply With Quote
Old 02-08-2010, 01:08 PM   #14
schoolteacher
Senior Member
 
Join Date: Feb 2008
Location: Georgia
Posts: 1,486
Re: San Antonio Summary

Thank you Joe.

Amelia
schoolteacher is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 02:43 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter